NiKang Therapeutics

NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.

NiKang Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Oncology sector. The company focuses on Biotechnology and has secured $12.5B in funding across 48 round(s). With a team of 11-50 employees, NiKang Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - NiKang Therapeutics, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.